Company: TELO
Filing Date: 2025-11-20
Form Type: PREM14A
Source: 0001493152-25-024463
Chunk: 211

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-20
Form: PREM14A
Chunk 211
---
 valuation, fairness opinions, common share valuation, purchase price allocations, employee stock option valuation, expert opinions, Feasibility Studies, and Pricing Analysis.

Recent projects include:

| ▪ | Fattal                                                                                              
 Hotels. Provided Fattal Hotels, a major European hotel & leisure company, with numerous             
 financial expert opinions, including a valuation and financial model requested by the underwriters, 
 in connection with Fattal’s IPO.                                                                    |
| ▪ | The                                                                                                 
 Second Authority for Television & Radio. Provided the Israeli Second Authority for                  
 Television & Radio with numerous economic studies and industry forecasts.                           |
| ▪ | El                                                                                                  
 Al. Provided El Al with valuations of two optional suppliers, which offered El Al an                
 equity shares as a benefit for selecting them as a supplier.                                        |
| ▪ | The                                                                                                 
 Israel Land Development Company. Provided the Israel Land Development Company, one of               
 the leading public companies in Israel, with numerous valuation studies of the company’s            
 major holdings.                                                                                     |
| ▪ | Given                                                                                               
 imaging. Various PPA and Impairment studies of Given Imaging SBUs (A global, leader in              
 patient-friendly solutions for visualizing, detecting, and monitoring GI disorders).                |
| ▪ | Kanit                                                                                               
 Hashalom. Numerous valuations of subsidiaries such as Tambour, Sonol, Supergas and GES.             |

Yours faithfully,

Moore Financial Consulting Ltd.

| Moore Financial Consulting |

| Telomir Pharmaceuticals, Inc.Valuation | November 2025Page 4 of 24 |

<div align='center'>Table of Contents</div>

| The                              
 Company                          |  5 |
| The                              
 Markets                          |  6 |
| Methodology                      | 11 |
| Valuation                        | 14 |
| Appendix                         
 – Benchmark Drugs and Treatments | 22 |

| Moore Financial Consulting |

| Telomir Pharmaceuticals, Inc.Valuation | November 2025Page 5 of 24 |

The Company

Telomir Pharmaceuticals, Inc. (“Telomir,” or the “Company”), is a pre-clinical-stage pharmaceutical development company.

Telomir-1 is a novel oral small molecule metal ion regulator designed to extend telomere caps, maintain cellular balance, and combat oxidative stress, a key driver of aging and disease progression. By modulating essential metal ions such as iron and copper, Telomir-1 may help protect against age-related conditions, including Progeria (